Literature DB >> 7472822

Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.

R Listernick1, C Darling, M Greenwald, L Strauss, J Charrow.   

Abstract

OBJECTIVE: To distinguish the clinical manifestations and natural history of optic pathway tumors (OPT) associated with neurofibromatosis type 1 (NF-1 OPT) from that of OPT not associated with NF-1 (non-NF-1 OPT).
METHODS: Two groups of children with OPT were compared: (1) 17 children with NF-1 OPT who were followed prospectively, and (2) 19 children with non-NF-1 OPT who were identified retrospectively by a review of medical records.
RESULTS: Precocious puberty was a common initial sign in the children with NF-1 OPT (5/17), and was not found in any patients without NF-1. In contrast, children with non-NF-1 OPT had symptoms attributable to increased intracranial pressure (12/19 and nystagmus (5/19); these symptoms were not found in any patient with NF-1. Decreased visual acuity at the time of diagnosis was common in both groups. There was no significant difference between the children with NF-1 OPT and those with non-NF-1 OPT as to age at diagnosis or sex distribution. Optic nerve involvement was more common in NF-1 (p < 0.001). Both isolated and bilateral optic nerve tumors were found exclusively in children with NF-1, whereas chiasmal (p = 0.016) and optic tract involvement (p = 0.001) were more common in those with non-NF-1 OPT. Radiographic evidence of hydrocephalus was found in none of the children with NF-1 OPT compared with 79% of the non-NF-1 OPT group. Progressive disease was seen in 12% of patients with NF-1 OPT compared with 63% of those with non-NF-1 OPT.
CONCLUSIONS: Differences exist between NF-1 OPT and non-NF-1 OPT both at the time of diagnosis and during follow-up. Optic pathway tumors caused by NF-1 and non-NF-1 OPT have different biologic properties that distinguish both their initial clinical manifestations and their natural history.

Entities:  

Mesh:

Year:  1995        PMID: 7472822     DOI: 10.1016/s0022-3476(95)70159-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

1.  Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.

Authors:  L Kornreich; S Blaser; M Schwarz; A Shuper; T H Vishne; I J Cohen; R Faingold; S Michovitz; B Koplewitz; G Horev
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

Review 3.  Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Authors:  Sabine Mueller; Susan Chang
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1.

Authors:  R Listernick; J Charrow; T Tomita; S Goldman
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Retinal nerve fiber layer thickness in children with optic pathway gliomas.

Authors:  Robert A Avery; Grant T Liu; Michael J Fisher; Graham E Quinn; Jean B Belasco; Peter C Phillips; Maureen G Maguire; Laura J Balcer
Journal:  Am J Ophthalmol       Date:  2011-01-12       Impact factor: 5.258

6.  Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas?

Authors:  Christina Schindera; Kevin Wingeier; Barbara Goeggel Simonetti; Miriam Diepold; Claude B Nauer; Johannes Fleischhauer; Maja Steinlin
Journal:  Childs Nerv Syst       Date:  2011-08-07       Impact factor: 1.475

7.  Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1).

Authors:  Christopher G Filippi; Aaron Bos; Joshua P Nickerson; Michael B Salmela; Chris J Koski; Keith A Cauley
Journal:  Pediatr Radiol       Date:  2011-08-21

8.  Remission of a chiasmatic glioma in a non-NF1 patient after brief chemotherapy with vincristine and carboplatin: case report and literature review.

Authors:  Elpis Mantadakis; Maria Raissaki; Vassiliki Danilatou; Alexander Kambourakis; Eftichia Stiakaki; Maria Kalmanti
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.

Authors:  A C Solga; S M Gianino; D H Gutmann
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 10.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.